ArticleJournal of cosmetic dermatology2025
Observation of Safety and Efficacy of Botulinum Toxin Type A in the Treatment of Tear Troughs and Mild Yelid Bags.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the safety and efficacy of Botulinum Toxin Type A (BTX-A) injection for the treatment of tear troughs.
methodThis study included patients with tear troughs rated as Grade 1-2 on the Barton Aesthetic Scale, who were treated between September 2023 and September 2024. These patients underwent intradermal injections of Botulinum Toxin Type A (BTX-A). Doctors conducted pre- and post-procedure assessments of the severity of tear troughs using the Barton Scale and TTRS (The Tear Trough Rating Scale). VISIA skin image analyzer (Canfield, USA) was utilized to compare the number of wrinkles, and facial scores and percentiles were calculated for objective evaluations before and after treatment. Additionally, doctors employed the Fitzpatrick Scale to assess periorbital wrinkles. This investigation was conducted as a prospective single-center study (PSS).
resultsAll 42 patients completed the study. After treatment, there was a significant improvement in VISIA-measured wrinkle count, facial scores, and percentiles. Additionally, there were significant reductions in Barton, TTRS, and Fitzpatrick scores. One case of pseudo-eyelid bags was observed post-treatment, while no other complications such as diplopia, lower eyelid skin laxity, or other adverse effects were reported.
conclusionBTX-A is effective in improving mild tear troughs while simultaneously reducing fine lines in the lower eyelid. Patients were highly satisfied with the improved appearance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.